Below you'll find a list of all posts that have been tagged as “Clinical Trials Unit News”
The last number of years have seen a proliferation of new innovative cancer drug therapies being tested in clinical trials at CCMB, nationally, and around the world. Some of these therapies have since become available for clinical use while many more are showing promise in current trials.
Septic shock, a life-threatening infection, is among the most common reasons for admission to ICUs in Manitoba and is a leading cause of death. Septic shock leads to uncontrolled inflammation and coagulation abnormalities. Apart from antibiotics and supportive care, there are few treatments available. Cancer patients are at higher risk of infections and septic shock due to immunosuppression from the underlying disease and chemotherapy.
Molecular testing has become more accessible for Manitobans living with cancer after physicians saw its importance in providing patients with the best possible treatment, based on their genetic profile. CCMB researchers conducted a study to test the effectiveness of a new class of medications, PARP inhibitors, in treating metastatic castrate-resistant prostate cancer patients with alterations within BRCA and ATM genes. …
